Mr. Murphy, If LLY is taking such actions other BP will as well. I wonder if this will "spoil" ongoing trials such as MDCOs PCSK-9 which is owned by NVS. If the study gets compromised the expected approval and use of that drug may be significantly delayed. One hopes that the situation will increase the odds of a deal getting done for a takeout of AMRN.